<![CDATA[CELMoD Wins “Landmark Approval” in Relapsed/Refractory Multiple Myeloma]]>
RegulatoryapprovedIberdomidePositive
AI Analysis
Summary
Iberdomide received landmark FDA approval for relapsed/refractory multiple myeloma as an oral therapy. The drug offers patients a convenient treatment option for this indication.
Outcome Details
Landmark approval for iberdomide in relapsed/refractory multiple myeloma
Importance:8/10
Sentiment:
0.85
FDA ApprovalMultiple MyelomaOral TherapyImmunomodulatory
Related Companies
Read the original article
Published by Cancer Network on August 26, 2026 1:00 PM